Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
Public ClinicalTrials.gov record NCT03051100. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Triplet Therapy With Bempedoic Acid (ETC 1002) 180 mg, Ezetimibe 10 mg, and Atorvastatin 20 mg in Patients With Elevated LDL C
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine if triplet therapy with bempedoic acid (ETC-1002) 180mg, ezetimibe 10mg, and atorvastatin 20mg is effective and safe versus placebo in patients with elevated LDL cholesterol.
Study identification
- NCT ID
- NCT03051100
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 63 participants
Conditions and interventions
Conditions
Interventions
- Bempedoic acid 180mg Drug
- Ezetimibe 10mg Drug
- Atorvastatin 20mg Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 18, 2017
- Primary completion
- May 31, 2017
- Completion
- Jul 4, 2017
- Last update posted
- Apr 2, 2020
2017
United States locations
- U.S. sites
- 11
- U.S. states
- 4
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| PMG Research of Christie Clinic | Champaign | Illinois | 61820 | — |
| PMG Research of Cary | Cary | North Carolina | 27518 | — |
| PMG Research of Charlotte | Charlotte | North Carolina | 28209 | — |
| Sensenbrenner Primary Care | Charlotte | North Carolina | 28277 | — |
| PMG Research of Hickory | Hickory | North Carolina | 28601 | — |
| PMG Research of Raleigh | Raleigh | North Carolina | 27609 | — |
| PMG Research of Rocky Mount | Rocky Mount | North Carolina | 27804 | — |
| PMG Research Salisbury | Salisbury | North Carolina | 28144 | — |
| PMG Research of Wilmington | Wilmington | North Carolina | 28401 | — |
| PMG Research of Charleston | Mt. Pleasant | South Carolina | 29464 | — |
| Hampton Roads Center for Clinical Research | Virginia Beach | Virginia | 23451 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03051100, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 2, 2020 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03051100 live on ClinicalTrials.gov.